FDA Approves Inluriyo Plus Verzenio for Breast Cancer
Analysis based on 6 articles · First reported Sep 18, 2026 · Last updated Sep 19, 2026
The approval expands Eli Lilly's oncology portfolio and provides a new combination regimen for a defined breast cancer population, supporting incremental revenue expectations for the company. It reinforces Lilly's competitive position in the oral SERD and CDK4/6 inhibitor space, though the immediate stock reaction was muted given the approval was widely anticipated.
Eli Lilly and Company announced that the U.S. United States — Food and Drug Administration granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in combination with Abemaciclib (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy. The approval is based on results from the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival to 11.1 months versus 5.5 months for Inluriyo alone, with a hazard ratio of 0.53. This marks the second FDA approval for Inluriyo in less than a year, following its September 2025 approval as monotherapy for the same patient population. Inluriyo is also being studied in the Phase 3 EMBER-4 trial in the adjuvant setting for early-stage breast cancer, with more than 8,000 patients enrolled across 650+ sites in 30+ countries and initial results anticipated in 2027. The combination is now available in the United States. Eli Lilly shares closed Friday at $1,152.93, up $0.49 or 0.04%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard